转战港股，海纳医药再谋上市

Core Viewpoint - Nanjing Haina Pharmaceutical Technology Co., Ltd. (referred to as "Haina Pharmaceutical") is attempting to enter the capital market by submitting an application to the Hong Kong Stock Exchange (HKEX) after previous unsuccessful attempts, facing declining revenue and net profit in the first half of the year [1][2][9]. Group 1: Company Overview - Haina Pharmaceutical is an integrated pharmaceutical research and manufacturing company that provides CXO services and has proprietary product pipelines, primarily commercialized through technology transfer [2]. - The company ranks second in China for the total number of approved clinical trials and market licenses during the reporting period [2]. Group 2: Financial Performance - In the first half of the year, Haina Pharmaceutical reported revenue of 178 million yuan and a net profit of 22.08 million yuan, down from 214 million yuan and 29.76 million yuan in the same period last year [7]. - The company's revenue and net profit have shown fluctuations from 2022 to 2024, with revenues of 265 million yuan, 410 million yuan, and 425 million yuan, and net profits of 59.77 million yuan, 73.02 million yuan, and 53.30 million yuan respectively [6][8]. Group 3: Market Strategy - Haina Pharmaceutical aims to use the funds raised from the HKEX listing to support research and development activities, expand production capacity, enhance quality control, and for general corporate purposes [2]. - The company has faced multiple challenges in its attempts to enter the capital market, including withdrawing its IPO application from the ChiNext and an unsuccessful acquisition attempt by Chengdu Xian Dao [9]. Group 4: Industry Insights - The HKEX offers advantages for companies like Haina Pharmaceutical, including flexible listing requirements, high international capital participation, and convenient refinancing mechanisms [3][5]. - The approval process at HKEX is more standardized and predictable, providing a more efficient financing channel for companies in need of funds [3].